FierceBiotech Apr 7, 2026 Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study
FierceBiotech Apr 6, 2026 Takeda tears up Denali partnership, returning dementia asset amid restructuring
FierceBiotech Apr 6, 2026 AI model designs new treatment candidate for opioid addiction that cuts cravings in rats
FierceBiotech Apr 6, 2026 With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
FierceBiotech Apr 6, 2026 US, UK regulators bolster medical device collaboration while lifting tariffs
FierceBiotech Apr 6, 2026 Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports
FierceBiotech Apr 6, 2026 Buoyed by $100M Series A, Stipple Bio debuts to advance lead oncology asset into clinic
FierceBiotech Apr 4, 2026 White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan
FierceBiotech Apr 3, 2026 ADCs, TCEs among ‘exciting things’ on Boehringer’s dealmaking shopping list
FierceBiotech Apr 3, 2026 Months after $100M series A, Syneron closes $150M round to support peptide platform